Register through Sept. 17 to receive the lowest rates for Advancing Gene + Cell Therapies for Cancer.
Learn about new approvals and the state of the field for each quarter of 2023.
In the first quarter, an mRNA vaccine was approved for COVID-19 prophylaxis in China; Vyznova, a non-genetically modified cell therapy, was approved for corneal dystrophy in Japan; and Hemgenix was approved for hemophilia B in the EU and UK.
In Q2, six new therapies were approved, including two gene therapies that are the first to be approved for their respective indications.
In Q3, an anti-BCMA-targeting CAR T-cell therapy, Fucaso, was approved for multiple myeloma in China and an mRNA vaccine, Daichirona, was approved for COVID-19 in Japan.
In the final quarter of 2023, FDA approved two cell-based gene therapies, Casgevy and Lyfgenia, to treat sickle cell disease. Casgevy represents the first-ever approval for a CRISPR-based therapeutic in the United States.
September 23-24, 2024 | Washington, D.C.
© 2000-2024 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico